VYNE News and Press, VYNE Therapeutics Inc Com From 12/06/21

Penny Stocks Insiders Decided To Buy This Month Who doesn’t like to take advantage of cheap prices? When it comes to penny stocks, compared to companies like Apple or Amazon, their prices may seem like they offer a steep discount. You also can’t forget that you’re a...

BRIDGEWATER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming Piper Sandler 33 rd Annual Virtual Healthcare Conf...

The following slide deck was published by VYNE Therapeutics Inc. in conjunction with their 2021 Q3 earnings call. For further details see: VYNE Therapeutics Inc. 2021 Q3 - Results - Earnings Call Presentation

VYNE Therapeutics Inc. (VYNE) Q3 2021 Earnings Conference Call November 10, 2021, 08:30 AM ET Company Participants John Fraunces – LifeSci Advisors Dave Domzalski – President and Chief Executive Officer Tyler Zeronda – Chief Financiial Officer Iain Stuart – Chief S...

VYNE Therapeutics (NASDAQ:VYNE): Q3 Non-GAAP EPS of -$0.36 misses by $0.04; GAAP EPS of -$0.41 misses by $0.09. Revenue of $4.09M (+25.1% Y/Y) misses by $0.67M. Shares -0.74% PM. Press Release For further details see: VYNE Therapeutics EPS misses by $0.04, misses on revenue

Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-to-Moderate Atopic Dermatitis Expected Early Q1 2022 Process for Sa...

VYNE Therapeutics (NASDAQ:VYNE) is scheduled to announce Q3 earnings results on Wednesday, November 10th, before market open. The consensus EPS Estimate is -$0.32 (-146.2% Y/Y) and the consensus Revenue Estimate is $4.76M (+45.6% Y/Y). Over the last 1 year, VYNE has beaten EPS estimates 100% ...

ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...

BRIDGEWATER, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced preclinical data from a validated animal study showing that its bromodomain and extra-terminal (“BET”) inhibitor, VY...

BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before ...